Institut Pasteur Korea – Hakim Djaballah, CEO
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
Institut Pasteur Korea is conceptualized around the virtual “genome to drugs” pipeline. The goal of IP-Korea is to actively implement post-genomic approaches into accelerated drug discovery. Accordingly, IP-Korea is situated at the very fault line between basic research and application.
The positioning of our institute is in good accordance with the Pasteurian tradition and mission. During its long history Institut Pasteur in Paris has been able to combine scientific achievements with their application in public health. This has improved the lives of millions of patients over the last 130 years, and has earned Institut Pasteur 10 Nobel prizes.
To extend and build on these achievements, IP-Korea is the first to develop a technology-based approach to therapeutic development in the areas of infectious and chronic diseases.
Strategically it combines its strength in biomedical research with Korean expertise in Information and Chemical technologies.
The result is the consequent implementation of visualization and imaging technology in analyzing disease models, accelerating both drug discovery and basic research.
Contact details
Address: 16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
Tel: +82 31 8018 8000
Fax: +82 31 8018 8010
Email: ipkorea@ip-korea.org
www.ip-korea.org
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
How did you first get involved in clinical trials and what inspired you to create your own CRO, ADM Korea? When I was working at CJ, the company was starting…
Could you please introduce KPMA and explain the role it plays within the South Korean pharmaceutical industry? KPMA is the only association in South Korea regrouping the whole range of…
LG Life Sciences seems quite unique among the rest of pharmaceutical companies in Korea which tend to be family owned. How has this set LGLS apart in terms of its…
Could you introduce Lee & Ko to our readers? Established in 1977, Lee & Ko is the largest and the leading law firm in Korea, consisting of 310 professionals, including…
South Korea has a short history of participating in global clinical trials, but now the country is seeing exponential growth in this area. What has changed in recent years leading…
What are the main milestones and achievements of Daewoong’s pharmaceutical business over its decades of evolution? Daewoong was first established in 1945 as Chosun Liver-oil Pharmaceutical Industry Co., Ltd. The…
You have been working in the CRM industry, particularly with pharmaceutical companies, for more then 10 years. Could you briefly introduce to our readers how the CRM industry has evolved…
Could you please give a brief presentation of Invest Korea to our readers? Invest Korea is the national investment promotion agency, responsible for attracting FDI into Korea. We have existed…
Boryung has a very interesting history, starting as a pharmacy in Seoul and going on to become one of the top 10 pharmaceutical companies in South Korea. What can you…
What drove you to make the move from the academia to the business sector when you decided to establish Medy-Tox in 2000? I founded Medy-tox in the year 2000, in…
What are the origins of Lundbeck in Korea and your involvement in its establishment? I joined Lundbeck just before it was officially established in Korea in April 2002. We started…
Though you have recently been appointed as President of KRIBB, your history with the institute goes quite far back. Could you please briefly explain the role it plays within South…
See our Cookie Privacy Policy Here
